Chimeric antigen receptor T-cell (CAR-T) therapy has become a groundbreaking treatment for hematologic malignancies, particularly in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and acute lymphoblastic leukemia (ALL). Building on its success in these indications, CAR-T therapy is now emerging as a promising option for patients with relapsed or refractory multiple myeloma (R/R MM), offering new hope for those with limited treatment options. However, the challenge of introducing CAR-T therapy into healthcare systems in Asia, is multifaceted. In an interview with Omnihealth Practice, Dr. Sivakumar Palaniappan, a consultant hematologist from Pantai Hospital Kuala Lumpur, Malaysia shed light on the region’s diverse healthcare landscape and the need for careful consideration of demographic, economic, and cultural factors to ensure broad and equitable access to this innovative treatment.

The field of immunotherapy has been rapidly evolving and is increasingly utilized in the management of lymphomas.¹ Currently, various immunotherapeutic modalities have been pursued including monoclonal antibodies, bispecific T-cell engagers (BiTEs), checkpoint inhibitors and chimeric antigen recepto

Currently, axicabtagene ciloleucel and tisagenlecleucel are two commercially available CAR-T treatment products approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Based on clinical trial results, these cell therapies have demonstrated durable overall response

Primary Sjögren’s Syndrome (pSS) is the second most prevalent systemic autoimmune disease characterized by ocular and oral dryness, musculoskeletal pain, profound fatigue, and an increased risk of lymphoma.¹ Although the symptoms are identifiable, pSS remains incurable due to its